{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,30]],"date-time":"2026-09-30T04:42:06Z","timestamp":1790743326329,"version":"4.1.0"},"reference-count":52,"publisher":"Springer Science and Business Media LLC","issue":"6","license":[{"start":{"date-parts":[[2006,4,27]],"date-time":"2006-04-27T00:00:00Z","timestamp":1146096000000},"content-version":"tdm","delay-in-days":0,"URL":"http:\/\/www.springer.com\/tdm"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Eur J Clin Pharmacol"],"published-print":{"date-parts":[[2006,6]]},"DOI":"10.1007\/s00228-006-0127-x","type":"journal-article","created":{"date-parts":[[2006,4,28]],"date-time":"2006-04-28T01:26:22Z","timestamp":1146187582000},"page":"451-461","source":"Crossref","is-referenced-by-count":57,"title":["Rifampicin is only a weak inducer of CYP1A2-mediated presystemic and systemic metabolism: studies with tizanidine and caffeine"],"prefix":"10.1007","volume":"62","author":[{"given":"Janne T.","family":"Backman","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Marika T.","family":"Granfors","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Pertti J.","family":"Neuvonen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2006,4,27]]},"reference":[{"key":"127_CR1","first-page":"197","volume":"17","author":"J Combalbert","year":"1989","unstructured":"Combalbert J, Fabre I, Fabre G, Dalet I, Derancourt J, Cano JP, Maurel P (1989) Metabolism of cyclosporin A. IV. Purification and identification of the rifampicin-inducible human liver cytochrome P-450 (cyclosporin A oxidase) as a product of P450IIIA gene subfamily. Drug Metab Dispos 17:197\u2013207","journal-title":"Drug Metab Dispos"},{"key":"127_CR2","doi-asserted-by":"crossref","first-page":"1871","DOI":"10.1172\/JCI116064","volume":"90","author":"JC Kolars","year":"1992","unstructured":"Kolars JC, Schmiedlin-Ren P, Schuetz JD, Fang C, Watkins PB (1992) Identification of rifampin-inducible P450IIIA4 (CYP3A4) in human small bowel enterocytes. J Clin Invest 90:1871\u20131878","journal-title":"J Clin Invest"},{"key":"127_CR3","doi-asserted-by":"crossref","first-page":"819","DOI":"10.2165\/00003088-200342090-00003","volume":"42","author":"M Niemi","year":"2003","unstructured":"Niemi M, Backman JT, Fromm MF, Neuvonen PJ, Kivist\u00f6 KT (2003) Pharmacokinetic interactions with rifampicin: clinical relevance. Clin Pharmacokinet 42:819\u2013850","journal-title":"Clin Pharmacokinet"},{"key":"127_CR4","doi-asserted-by":"crossref","first-page":"7","DOI":"10.1016\/S0009-9236(96)90018-1","volume":"59","author":"JT Backman","year":"1996","unstructured":"Backman JT, Olkkola KT, Neuvonen PJ (1996) Rifampin drastically reduces plasma concentrations and effects of oral midazolam. Clin Pharmacol Ther 59:7\u201313","journal-title":"Clin Pharmacol Ther"},{"key":"127_CR5","doi-asserted-by":"crossref","first-page":"8","DOI":"10.1016\/S0009-9236(97)90176-4","volume":"61","author":"K Villikka","year":"1997","unstructured":"Villikka K, Kivist\u00f6 KT, Backman JT, Olkkola KT, Neuvonen PJ (1997) Triazolam is ineffective in patients taking rifampin. Clin Pharmacol Ther 61:8\u201314","journal-title":"Clin Pharmacol Ther"},{"key":"127_CR6","doi-asserted-by":"crossref","first-page":"381","DOI":"10.1046\/j.1365-2125.1998.t01-1-00698.x","volume":"45","author":"TS Lamberg","year":"1998","unstructured":"Lamberg TS, Kivist\u00f6 KT, Neuvonen PJ (1998) Concentrations and effects of buspirone are considerably reduced by rifampicin. Br J Clin Pharmacol 45:381\u2013385","journal-title":"Br J Clin Pharmacol"},{"key":"127_CR7","doi-asserted-by":"crossref","first-page":"592","DOI":"10.1067\/mcp.2000.111414","volume":"68","author":"C Kyrklund","year":"2000","unstructured":"Kyrklund C, Backman JT, Kivist\u00f6 KT, Neuvonen M, Laitila J, Neuvonen PJ (2000) Rifampin greatly reduces plasma simvastatin and simvastatin acid concentrations. Clin Pharmacol Ther 68:592\u2013597","journal-title":"Clin Pharmacol Ther"},{"key":"127_CR8","doi-asserted-by":"crossref","first-page":"147","DOI":"10.1172\/JCI6663","volume":"104","author":"B Greiner","year":"1999","unstructured":"Greiner B, Eichelbaum M, Fritz P, Kreichgauer HP, von Richter O, Zundler J, Kroemer HK (1999) The role of intestinal P-glycoprotein in the interaction of digoxin and rifampin. J Clin Invest 104:147\u2013153","journal-title":"J Clin Invest"},{"key":"127_CR9","doi-asserted-by":"crossref","first-page":"1575","DOI":"10.1016\/S0002-9440(10)64794-3","volume":"157","author":"MF Fromm","year":"2000","unstructured":"Fromm MF, Kauffmann HM, Fritz P, Burk O, Kroemer HK, Warzok RW, Eichelbaum M, Siegmund W, Schrenk D (2000) The effect of rifampin treatment on intestinal expression of human MRP transporters. Am J Pathol 157:1575\u20131580","journal-title":"Am J Pathol"},{"key":"127_CR10","doi-asserted-by":"crossref","first-page":"445","DOI":"10.1111\/j.1365-2125.1984.tb02487.x","volume":"18","author":"RA Robson","year":"1984","unstructured":"Robson RA, Miners JO, Wing LM, Birkett DJ (1984) Theophylline-rifampicin interaction: non-selective induction of theophylline metabolic pathways. Br J Clin Pharmacol 18:445\u2013448","journal-title":"Br J Clin Pharmacol"},{"key":"127_CR11","doi-asserted-by":"crossref","first-page":"153","DOI":"10.1097\/00007691-198406000-00004","volume":"6","author":"AB Straughn","year":"1984","unstructured":"Straughn AB, Henderson RP, Lieberman PL, Self TH (1984) Effect of rifampin on theophylline disposition. Ther Drug Monit 6:153\u2013156","journal-title":"Ther Drug Monit"},{"key":"127_CR12","doi-asserted-by":"crossref","first-page":"78","DOI":"10.1016\/0168-8278(95)80263-0","volume":"22","author":"H Wietholtz","year":"1995","unstructured":"Wietholtz H, Zysset T, Marschall HU, Generet K, Matern S (1995) The influence of rifampin treatment on caffeine clearance in healthy man. J Hepatol 22:78\u201381","journal-title":"J Hepatol"},{"key":"127_CR13","doi-asserted-by":"crossref","first-page":"736","DOI":"10.1177\/106002809603000705","volume":"30","author":"J Soto","year":"1996","unstructured":"Soto J, Sacristan JA, Alsar MJ (1996) Use of salivary caffeine tests to assess the inducer effect of a drug on hepatic metabolism. Ann Pharmacother 30:736\u2013739","journal-title":"Ann Pharmacother"},{"key":"127_CR14","doi-asserted-by":"crossref","first-page":"344","DOI":"10.1016\/S0009-9236(01)29243-1","volume":"70","author":"MJ Jokinen","year":"2001","unstructured":"Jokinen MJ, Olkkola KT, Ahonen J, Neuvonen PJ (2001) Effect of rifampin and tobacco smoking on the pharmacokinetics of ropivacaine. Clin Pharmacol Ther 70:344\u2013350","journal-title":"Clin Pharmacol Ther"},{"key":"127_CR15","first-page":"31","volume":"20","author":"MA Sarkar","year":"1992","unstructured":"Sarkar MA, Hunt C, Guzelian PS, Karnes HT (1992) Characterization of human liver cytochromes P-450 involved in theophylline metabolism. Drug Metab Dispos 20:31\u201337","journal-title":"Drug Metab Dispos"},{"key":"127_CR16","doi-asserted-by":"crossref","first-page":"151","DOI":"10.1111\/j.1365-2125.1995.tb04422.x","volume":"39","author":"BB Rasmussen","year":"1995","unstructured":"Rasmussen BB, M\u00e4enp\u00e4\u00e4 J, Pelkonen O, Loft S, Poulsen HE, Lykkesfeldt J, Br\u00f8sen K (1995) Selective serotonin reuptake inhibitors and theophylline metabolism in human liver microsomes: potent inhibition by fluvoxamine. Br J Clin Pharmacol 39:151\u2013159","journal-title":"Br J Clin Pharmacol"},{"key":"127_CR17","first-page":"912","volume":"276","author":"JF Tjia","year":"1996","unstructured":"Tjia JF, Colbert J, Back DJ (1996) Theophylline metabolism in human liver microsomes: inhibition studies. J Pharmacol Exp Ther 276:912\u2013917","journal-title":"J Pharmacol Exp Ther"},{"key":"127_CR18","first-page":"617","volume":"25","author":"T Shimada","year":"1997","unstructured":"Shimada T, Gillam EM, Sutter TR, Strickland PT, Guengerich FP, Yamazaki H (1997) Oxidation of xenobiotics by recombinant human cytochrome P450 1B1. Drug Metab Dispos 25:617\u2013622","journal-title":"Drug Metab Dispos"},{"key":"127_CR19","doi-asserted-by":"crossref","first-page":"7696","DOI":"10.1073\/pnas.86.20.7696","volume":"86","author":"MA Butler","year":"1989","unstructured":"Butler MA, Iwasaki M, Guengerich FP, Kadlubar FF (1989) Human cytochrome P-450PA (P-450IA2), the phenacetin O-deethylase, is primarily responsible for the hepatic 3-demethylation of caffeine and N-oxidation of carcinogenic arylamines. Proc Natl Acad Sci USA 86:7696\u20137700","journal-title":"Proc Natl Acad Sci USA"},{"key":"127_CR20","doi-asserted-by":"crossref","first-page":"173","DOI":"10.1097\/00008571-199208000-00004","volume":"2","author":"W Tassaneeyakul","year":"1992","unstructured":"Tassaneeyakul W, Mohamed Z, Birkett DJ, McManus ME, Veronese ME, Tukey RH, Quattrochi LC, Gonzalez FJ, Miners JO (1992) Caffeine as a probe for human cytochromes P450: validation using cDNA-expression, immunoinhibition and microsomal kinetic and inhibitor techniques. Pharmacogenetics 2:173\u2013183","journal-title":"Pharmacogenetics"},{"key":"127_CR21","doi-asserted-by":"crossref","first-page":"1767","DOI":"10.1016\/0006-2952(94)90304-2","volume":"47","author":"W Tassaneeyakul","year":"1994","unstructured":"Tassaneeyakul W, Birkett DJ, McManus ME, Veronese ME, Andersson T, Tukey RH, Miners JO (1994) Caffeine metabolism by human hepatic cytochromes P450: contributions of 1A2, 2E1 and 3A isoforms. Biochem Pharmacol 47:1767\u20131776","journal-title":"Biochem Pharmacol"},{"key":"127_CR22","doi-asserted-by":"crossref","first-page":"309","DOI":"10.1007\/BF00226333","volume":"49","author":"HR Ha","year":"1996","unstructured":"Ha HR, Chen J, Kr\u00e4henb\u00fchl S, Follath F (1996) Biotransformation of caffeine by cDNA-expressed human cytochromes P-450. Eur J Clin Pharmacol 49:309\u2013315","journal-title":"Eur J Clin Pharmacol"},{"key":"127_CR23","first-page":"955","volume":"24","author":"G Ekstr\u00f6m","year":"1996","unstructured":"Ekstr\u00f6m G, Gunnarsson UB (1996) Ropivacaine, a new amide-type local anesthetic agent, is metabolized by cytochromes P450 1A and 3A in human liver microsomes. Drug Metab Dispos 24:955\u2013961","journal-title":"Drug Metab Dispos"},{"key":"127_CR24","doi-asserted-by":"crossref","first-page":"484","DOI":"10.1016\/S0009-9236(98)90131-X","volume":"64","author":"E Arlander","year":"1998","unstructured":"Arlander E, Ekstr\u00f6m G, Alm C, Carrillo JA, Bielenstein M, B\u00f6ttiger Y, Bertilsson L, Gustafsson LL (1998) Metabolism of ropivacaine in humans is mediated by CYP1A2 and to a minor extent by CYP3A4: an interaction study with fluvoxamine and ketoconazole as in vivo inhibitors. Clin Pharmacol Ther 64:484\u2013491","journal-title":"Clin Pharmacol Ther"},{"key":"127_CR25","doi-asserted-by":"crossref","first-page":"619","DOI":"10.1124\/dmd.104.003301","volume":"33","author":"Y Kobayashi","year":"2005","unstructured":"Kobayashi Y, Sakai R, Ohshiro N, Ohbayashi M, Kohyama N, Yamamoto T (2005) Possible involvement of organic anion transporter 2 on the interaction of theophylline with erythromycin in the human liver. Drug Metab Dispos 33:619\u2013622","journal-title":"Drug Metab Dispos"},{"key":"127_CR26","doi-asserted-by":"crossref","first-page":"4936","DOI":"10.1016\/S0021-9258(17)33205-2","volume":"251","author":"A Poland","year":"1976","unstructured":"Poland A, Glover E, Kende AS (1976) Stereospecific, high affinity binding of 2,3,7,8-tetrachlorodibenzo-p-dioxin by hepatic cytosol. Evidence that the binding species is receptor for induction of aryl hydrocarbon hydroxylase. J Biol Chem 251:4936\u20134946","journal-title":"J Biol Chem"},{"key":"127_CR27","doi-asserted-by":"crossref","first-page":"1169","DOI":"10.1002\/jps.20324","volume":"94","author":"RG Tirona","year":"2005","unstructured":"Tirona RG, Kim RB (2005) Nuclear receptors and drug disposition gene regulation. J Pharm Sci 94:1169\u20131186","journal-title":"J Pharm Sci"},{"key":"127_CR28","doi-asserted-by":"crossref","first-page":"109","DOI":"10.1097\/00008571-199406000-00001","volume":"4","author":"U Fuhr","year":"1994","unstructured":"Fuhr U, Rost KL (1994) Simple and reliable CYP1A2 phenotyping by the paraxanthine\/caffeine ratio in plasma and in saliva. Pharmacogenetics 4:109\u2013116","journal-title":"Pharmacogenetics"},{"key":"127_CR29","doi-asserted-by":"crossref","first-page":"159","DOI":"10.1097\/00008571-199604000-00003","volume":"6","author":"U Fuhr","year":"1996","unstructured":"Fuhr U, Rost KL, Engelhardt R, Sachs M, Liermann D, Belloc C, Beaune P, Janezic S, Grant D, Meyer UA, Staib AH (1996) Evaluation of caffeine as a test drug for CYP1A2, NAT2 and CYP2E1 phenotyping in man by in vivo versus in vitro correlations. Pharmacogenetics 6:159\u2013176","journal-title":"Pharmacogenetics"},{"key":"127_CR30","doi-asserted-by":"crossref","first-page":"409","DOI":"10.1097\/00008571-199906000-00019","volume":"9","author":"O Spigset","year":"1999","unstructured":"Spigset O, H\u00e4gg S, S\u00f6derstr\u00f6m E, Dahlqvist R (1999) The paraxanthine:caffeine ratio in serum or in saliva as a measure of CYP1A2 activity: when should the sample be obtained? Pharmacogenetics 9:409\u2013412","journal-title":"Pharmacogenetics"},{"key":"127_CR31","doi-asserted-by":"crossref","first-page":"125","DOI":"10.1111\/j.1742-7843.2005.pto_973160.x","volume":"97","author":"MS Faber","year":"2005","unstructured":"Faber MS, Jetter A, Fuhr U (2005) Assessment of CYP1A2 activity in clinical practice: why, how, and when? Basic Clin Pharmacol Toxicol 97:125\u2013134","journal-title":"Basic Clin Pharmacol Toxicol"},{"key":"127_CR32","first-page":"C4","volume-title":"Therapeutic drugs","author":"C Dollery","year":"1999","unstructured":"Dollery C (1999) Caffeine. In: Dollery C (ed) Therapeutic drugs. Churchill Livingstone, Edinburgh, pp\u00a0C4\u2013C6"},{"key":"127_CR33","doi-asserted-by":"crossref","first-page":"1255","DOI":"10.3109\/00498258909043177","volume":"19","author":"P Koch","year":"1989","unstructured":"Koch P, Hirst DR, von Wartburg BR (1989) Biological fate of sirdalud in animals and man. Xenobiotica 19:1255\u20131265","journal-title":"Xenobiotica"},{"key":"127_CR34","doi-asserted-by":"crossref","first-page":"349","DOI":"10.1046\/j.1365-2125.2003.02028.x","volume":"57","author":"MT Granfors","year":"2004","unstructured":"Granfors MT, Backman JT, Laitila J, Neuvonen PJ (2004) Tizanidine is mainly metabolized by cytochrome p450 1A2 in vitro. Br J Clin Pharmacol 57:349\u2013353","journal-title":"Br J Clin Pharmacol"},{"key":"127_CR35","doi-asserted-by":"crossref","first-page":"331","DOI":"10.1016\/j.clpt.2003.12.005","volume":"75","author":"MT Granfors","year":"2004","unstructured":"Granfors MT, Backman JT, Neuvonen M, Ahonen J, Neuvonen PJ (2004) Fluvoxamine drastically increases concentrations and effects of tizanidine: a potentially hazardous interaction. Clin Pharmacol Ther 75:331\u2013341","journal-title":"Clin Pharmacol Ther"},{"key":"127_CR36","doi-asserted-by":"crossref","first-page":"1211","DOI":"10.1016\/0006-2952(93)90272-X","volume":"45","author":"K Br\u00f8sen","year":"1993","unstructured":"Br\u00f8sen K, Skjelbo E, Rasmussen BB, Poulsen HE, Loft S (1993) Fluvoxamine is a potent inhibitor of cytochrome P4501A2. Biochem Pharmacol 45:1211\u20131214","journal-title":"Biochem Pharmacol"},{"key":"127_CR37","doi-asserted-by":"crossref","first-page":"89S","DOI":"10.1016\/0002-9343(89)90031-4","volume":"87","author":"S Harder","year":"1989","unstructured":"Harder S, Fuhr U, Staib AH, Wolff T (1989) Ciprofloxacin-caffeine: a drug interaction established using in vivo and in vitro investigations. Am J Med 87:89S\u201391S","journal-title":"Am J Med"},{"key":"127_CR38","doi-asserted-by":"crossref","first-page":"598","DOI":"10.1016\/j.clpt.2004.08.018","volume":"76","author":"MT Granfors","year":"2004","unstructured":"Granfors MT, Backman JT, Neuvonen M, Neuvonen PJ (2004) Ciprofloxacin greatly increases concentrations and hypotensive effect of tizanidine by inhibiting its cytochrome P450 1A2-mediated presystemic metabolism. Clin Pharmacol Ther 76:598\u2013606","journal-title":"Clin Pharmacol Ther"},{"key":"127_CR39","doi-asserted-by":"crossref","first-page":"440","DOI":"10.1177\/000456328602300410","volume":"23","author":"CE Pickard","year":"1986","unstructured":"Pickard CE, Stewart AD, Hartley R, Lucock MD (1986) A rapid HPLC method for monitoring plasma levels of caffeine and theophylline using solid phase extraction columns. Ann Clin Biochem 23:440\u2013446","journal-title":"Ann Clin Biochem"},{"key":"127_CR40","doi-asserted-by":"crossref","first-page":"105","DOI":"10.1016\/S0378-4347(97)00590-2","volume":"707","author":"DT Holland","year":"1998","unstructured":"Holland DT, Godfredsen KA, Page T, Connor JD (1998) Simple high-performance liquid chromatography method for the simultaneous determination of serum caffeine and paraxanthine following rapid sample preparation. J Chromatogr B Biomed Sci Appl 707:105\u2013110","journal-title":"J Chromatogr B Biomed Sci Appl"},{"key":"127_CR41","doi-asserted-by":"crossref","first-page":"1016","DOI":"10.1172\/JCI3703","volume":"102","author":"JM Lehmann","year":"1998","unstructured":"Lehmann JM, McKee DD, Watson MA, Willson TM, Moore JT, Kliewer SA (1998) The human orphan nuclear receptor PXR is activated by compounds that regulate CYP3A4 gene expression and cause drug interactions. J Clin Invest 102:1016\u20131023","journal-title":"J Clin Invest"},{"key":"127_CR42","doi-asserted-by":"crossref","first-page":"172","DOI":"10.1080\/07853890310008224","volume":"35","author":"P Honkakoski","year":"2003","unstructured":"Honkakoski P, Sueyoshi T, Negishi M (2003) Drug-activated nuclear receptors CAR and PXR. Ann Med 35:172\u2013182","journal-title":"Ann Med"},{"key":"127_CR43","doi-asserted-by":"crossref","first-page":"849","DOI":"10.1016\/S0022-3565(24)29202-8","volume":"299","author":"JM Rae","year":"2001","unstructured":"Rae JM, Johnson MD, Lippman ME, Flockhart DA (2001) Rifampin is a selective, pleiotropic inducer of drug metabolism genes in human hepatocytes: studies with cDNA and oligonucleotide expression arrays. J Pharmacol Exp Ther 299:849\u2013857","journal-title":"J Pharmacol Exp Ther"},{"key":"127_CR44","doi-asserted-by":"crossref","first-page":"437","DOI":"10.1111\/j.1432-1033.1990.tb19140.x","volume":"191","author":"F Morel","year":"1990","unstructured":"Morel F, Beaune PH, Ratanasavanh D, Flinois JP, Yang CS, Guengerich FP, Guillouzo A (1990) Expression of cytochrome P-450 enzymes in cultured human hepatocytes. Eur J Biochem 191:437\u2013444","journal-title":"Eur J Biochem"},{"key":"127_CR45","doi-asserted-by":"crossref","first-page":"17","DOI":"10.1016\/S0009-2797(97)00071-9","volume":"107","author":"AP Li","year":"1997","unstructured":"Li AP, Reith MK, Rasmussen A, Gorski JC, Hall SD, Xu L, Kaminski DL, Cheng LK (1997) Primary human hepatocytes as a tool for the evaluation of structure-activity relationship in cytochrome P450 induction potential of xenobiotics: evaluation of rifampin, rifapentine and rifabutin. Chem Biol Interact 107:17\u201330","journal-title":"Chem Biol Interact"},{"key":"127_CR46","doi-asserted-by":"crossref","first-page":"303","DOI":"10.1124\/jpet.103.061713","volume":"309","author":"JB Mills","year":"2004","unstructured":"Mills JB, Rose KA, Sadagopan N, Sahi J, de Morais SM (2004) Induction of drug metabolism enzymes and MDR1 using a novel human hepatocyte cell line. J Pharmacol Exp Ther 309:303\u2013309","journal-title":"J Pharmacol Exp Ther"},{"key":"127_CR47","doi-asserted-by":"crossref","first-page":"427","DOI":"10.1016\/j.bcp.2003.09.022","volume":"67","author":"D Roymans","year":"2004","unstructured":"Roymans D, Van Looveren C, Leone A, Parker JB, McMillian M, Johnson MD, Koganti A, Gilissen R, Silber P, Mannens G, Meuldermans W (2004) Determination of cytochrome P450 1A2 and cytochrome P450 3A4 induction in cryopreserved human hepatocytes. Biochem Pharmacol 67:427\u2013437","journal-title":"Biochem Pharmacol"},{"key":"127_CR48","doi-asserted-by":"crossref","first-page":"638","DOI":"10.1124\/mol.62.3.638","volume":"62","author":"JM Maglich","year":"2002","unstructured":"Maglich JM, Stoltz CM, Goodwin B, Hawkins-Brown D, Moore JT, Kliewer SA (2002) Nuclear pregnane x receptor and constitutive androstane receptor regulate overlapping but distinct sets of genes involved in xenobiotic detoxification. Mol Pharmacol 62:638\u2013646","journal-title":"Mol Pharmacol"},{"key":"127_CR49","doi-asserted-by":"crossref","first-page":"421","DOI":"10.1124\/dmd.31.4.421","volume":"31","author":"A Madan","year":"2003","unstructured":"Madan A, Graham RA, Carroll KM, Mudra DR, Burton LA, Krueger LA, Downey AD, Czerwinski M, Forster J, Ribadeneira MD, Gan LS, LeCluyse EL, Zech K, Robertson P, Jr., Koch P, Antonian L, Wagner G, Yu L, Parkinson A (2003) Effects of prototypical microsomal enzyme inducers on cytochrome P450 expression in cultured human hepatocytes. Drug Metab Dispos 31:421\u2013431","journal-title":"Drug Metab Dispos"},{"key":"127_CR50","doi-asserted-by":"crossref","first-page":"435","DOI":"10.2165\/00003495-199753030-00007","volume":"53","author":"AJ Wagstaff","year":"1997","unstructured":"Wagstaff AJ, Bryson HM (1997) Tizanidine. A review of its pharmacology, clinical efficacy and tolerability in the management of spasticity associated with cerebral and spinal disorders. Drugs 53:435\u2013452","journal-title":"Drugs"},{"key":"127_CR51","doi-asserted-by":"crossref","first-page":"400","DOI":"10.1016\/j.clpt.2005.06.009","volume":"78","author":"MT Granfors","year":"2005","unstructured":"Granfors MT, Backman JT, Laitila J, Neuvonen PJ (2005) Oral contraceptives containing ethinyl estradiol and gestodene markedly increase plasma concentrations and effects of tizanidine by inhibiting cytochrome P450 1A2. Clin Pharmacol Ther 78:400\u2013411","journal-title":"Clin Pharmacol Ther"},{"key":"127_CR52","doi-asserted-by":"crossref","first-page":"401","DOI":"10.1067\/mcp.2000.110561","volume":"68","author":"RA Branch","year":"2000","unstructured":"Branch RA, Adedoyin A, Frye RF, Wilson JW, Romkes M (2000) In vivo modulation of CYP enzymes by quinidine and rifampin. Clin Pharmacol Ther 68:401\u2013411","journal-title":"Clin Pharmacol Ther"}],"container-title":["European Journal of Clinical Pharmacology"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s00228-006-0127-x.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/article\/10.1007\/s00228-006-0127-x\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s00228-006-0127-x","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,1,8]],"date-time":"2025-01-08T18:25:24Z","timestamp":1736360724000},"score":1,"resource":{"primary":{"URL":"http:\/\/link.springer.com\/10.1007\/s00228-006-0127-x"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2006,4,27]]},"references-count":52,"journal-issue":{"issue":"6","published-print":{"date-parts":[[2006,6]]}},"alternative-id":["127"],"URL":"https:\/\/doi.org\/10.1007\/s00228-006-0127-x","relation":{},"ISSN":["0031-6970","1432-1041"],"issn-type":[{"value":"0031-6970","type":"print"},{"value":"1432-1041","type":"electronic"}],"subject":[],"published":{"date-parts":[[2006,4,27]]}}}